GYRE

Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. (GYRE) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Momentum (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C
Factor Score 2.2 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 71.0
EV / EBITDA -29.6
Rev Growth YoY 0.7%
Gross Margin 93.5%
Price Return 3M -34.9%
Price Return 12M -46.2%
Catalyst Signal 0.00
Market Cap $466.3M
TTM Revenue $110.1M
Price / Sales 4.2
ROE -17.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C (2.2) C (2.4) C+ (2.8) C (2.2) C+ (2.6) C (2.5)
2026-11-05 C (2.2) C (2.3) C+ (2.8) C (2.3) C+ (2.7) C (2.5)
2026-10-29 D+ (1.7) C (2.3) C+ (2.8) B- (3.1) C+ (2.7) C+ (2.5)
2026-10-22 C- (1.9) C (2.3) C+ (2.8) C+ (2.7) C+ (2.6) C (2.5)
2026-10-15 D+ (1.8) C (2.3) C+ (2.8) C (2.5) C+ (2.6) C (2.4)
Page 1 of 4